Advances on cardiovascular effects of GLP-lRAs

Zhi-qiang KE; Chao Liu; Zhi-qiang KE; Qian-qian MA; Zheng-ding SU; Dan LI; Xin-yuan Zhao

Return

Advances on cardiovascular effects of GLP-lRAs

Author: Zhi-Qiang KE ¹ ; Chao LIU ¹ ; Zhi-Qiang KE ² ; Qian-Qian MA ² ; Zheng-Ding SU ² ; Dan LI ³ ; Xin-Yuan ZHAO ⁴
Author Information

1. Hubei Key Laboratory of Diabetes and Angiopathy, Xianning Medical College, Hubei University of Science and Technology
2. Cooperative Innovation Center of Industrial Fermentation (Ministry of Education and Hubei Province), Hubei University of Technology
3. Department of Neonatology, Xianning Central Hospital/First Affiliated Hospital of Hubei University of Science and Technology
4. National Demonstration Center for Experimental General Medicine Education, Xianning Medical College, Hubei University of Science and Technology
Publication Type:Journal Article
Keywords: cardiovascular diseases; GLP-1 RAs; glucagon-like peptide-1; oral GLP-1 RAs; small-molecule GLP-1 RAs; type 2 diabetes
From: Chinese Pharmacological Bulletin 2024;40(3):426-430
CountryChina
Language:Chinese
Abstract: Glucagon-like peptide-1 ( GLP-1 ) is secreted by gut enteroendocrine cells. GLP-1 receptor agonists ( GLP-1 RAs) control glucose-related augmentation of insulin and suppress glu-cagon secretion. GLP-lRAs also inhibit gastric emptying, food intake and limit weight gain. In the past decade, significant progresses have been made in the investigation on the effects of GLP-1 RAs on cardiovascular system. The potential advantages of oral small-molecule GLP-1 RAs could improve the application of this class of drugs. This review highlights the multiple cardiovascular profiles of GLP-1 RAs in the treatment of cardiovascular diseases to provide new insights into cardiovascular benefits of GLP-1 RAs.